U.S. patent application number 13/700091 was filed with the patent office on 2013-04-04 for crosslinker enhanced repair of knee meniscus.
This patent application is currently assigned to Orthopeutics, L.P.. The applicant listed for this patent is Thomas P. Hedman, Paul Slusarewicz. Invention is credited to Thomas P. Hedman, Paul Slusarewicz.
Application Number | 20130085569 13/700091 |
Document ID | / |
Family ID | 45004384 |
Filed Date | 2013-04-04 |
United States Patent
Application |
20130085569 |
Kind Code |
A1 |
Hedman; Thomas P. ; et
al. |
April 4, 2013 |
CROSSLINKER ENHANCED REPAIR OF KNEE MENISCUS
Abstract
A method of treating a tear in a knee meniscus of a patient. The
method includes exposing the torn knee meniscus to a protein
crosslinker during surgery to repair the tear. Also provided is a
fixation device for the surgical repair of tears of the meniscus of
the knee, where the device contains one or more protein
crosslinking reagents.
Inventors: |
Hedman; Thomas P.;
(Lexington, KY) ; Slusarewicz; Paul; (Lexington,
KY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Hedman; Thomas P.
Slusarewicz; Paul |
Lexington
Lexington |
KY
KY |
US
US |
|
|
Assignee: |
Orthopeutics, L.P.
Lexington
KY
|
Family ID: |
45004384 |
Appl. No.: |
13/700091 |
Filed: |
May 26, 2011 |
PCT Filed: |
May 26, 2011 |
PCT NO: |
PCT/US11/38155 |
371 Date: |
December 13, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61348977 |
May 27, 2010 |
|
|
|
Current U.S.
Class: |
623/14.12 |
Current CPC
Class: |
A61L 27/58 20130101;
A61L 31/043 20130101; A61L 2300/412 20130101; A61F 2/3872 20130101;
A61L 31/14 20130101; A61L 27/54 20130101; A61F 2/30756 20130101;
A61L 27/34 20130101; A61F 2250/0067 20130101; A61F 2/0063 20130101;
A61L 2430/06 20130101; A61L 27/18 20130101; A61L 27/505
20130101 |
Class at
Publication: |
623/14.12 |
International
Class: |
A61F 2/30 20060101
A61F002/30 |
Claims
1. A method of treating a tear in a knee meniscus of a patient,
comprising contacting a torn knee meniscus with a delivery device
comprising a protein crosslinking agent during surgery to repair
the tear, wherein the crosslinking agent increases the number of
covalent crosslink bonds in native tissue in the knee meniscus.
2. The method of claim 1, wherein the delivery device comprises a
patch or fixation device comprising the crosslinking agent.
3. The method of claim 2, wherein the fixation device is an arrow,
dart, tack or suture.
4. The method of claim 2, wherein the patch or fixation device is
biodegradable.
5. The method of claim 2, wherein the patch or fixation device
further comprises a basic salt.
6. The method of claim 5, wherein the basic salt is calcium
carbonate, calcium hydroxyapatite, sodium bicarbonate,
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
7. The method of claim 2, wherein the patch is
non-biodegradable.
8. The method of claim 2, wherein the patch is porous and the
crosslinking agent is embedded within the pores.
9. The method of claim 2, wherein the crosslinking agent is adhered
to one side of the patch as part of a semi-solid formulation.
10. The method of claim 2, wherein the patch or fixation device is
coated with one or more layers of crosslinking agent-containing
biodegradable polymer.
11. The method of claim 10, wherein each layer comprises a basic
salt.
12. The method of claim 11, wherein the salt is calcium carbonate,
calcium hydroxyapatite, sodium bicarbonate,
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
13. The method of claim 10, wherein the patch or fixation device is
coated with multiple layers of crosslinking agent-containing
biodegradable polymer, and the crosslinking agent varies from layer
to layer.
14. The method of claim 2, wherein the patch is affixed to the
meniscus with a bio-compatible adhesive.
15. The method of claim 14, wherein the adhesive is
poly(glycerol-co-sebacate acrylate), an oleic methyl ester or an
alkyl ester cyanoacrylate.
16. The method of claim 2, wherein the patch is affixed to the
meniscus by an associated fixation device.
17. The method of claim 16, wherein the associated fixation device
is an arrow, dart, tack or suture.
18. The method of claim 16, wherein the associated fixation device
comprises a crosslinking agent.
19. A delivery device for contacting the knee meniscus of a
patient, the device comprising a patch or fixation device
comprising a protein crosslinking agent.
20. The delivery device of claim 19, wherein the fixation device is
an arrow, dart, tack or suture.
21. The delivery device of claim 19, wherein the patch or fixation
device is biodegradable.
22. The delivery device of claim 19, wherein the patch or fixation
device further comprises a basic salt.
23. The delivery device of claim 22, wherein the basic salt is
calcium carbonate, calcium hydroxyapatite, sodium bicarbonate,
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
24. The delivery device of claim 19, wherein the patch is porous
and the crosslinking agent is embedded within the pores.
25. The delivery device of claim 19, wherein the crosslinking agent
is adhered to one side of the patch as part of a semi-solid
formulation
26. The delivery device of claim 19, wherein the patch or fixation
device is coated with one or more layers of crosslinking
agent-containing biodegradable polymer.
27. The delivery device of claim 26, wherein each layer comprises a
basic salt.
28. The delivery device of claim 27, wherein the salt is calcium
carbonate, calcium hydroxyapatite, sodium bicarbonate,
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
29. The delivery device of claim 26, wherein the patch or fixation
device is coated with multiple layers of crosslinking
agent-containing biodegradable polymer, and the crosslinking agent
varies from layer to layer.
30. The delivery device of claim 19, wherein the patch is affixed
to the meniscus with a bio-compatible adhesive.
31. The delivery device of claim 30, wherein the adhesive is
poly(glycerol-co-sebacate acrylate), an oleic methyl ester or an
alkyl ester cyanoacrylate.
32. The delivery device of claim 19, wherein the patch is affixed
to the meniscus by an associated fixation device.
33. The delivery device of claim 32, wherein the associated
fixation device is an arrow, dart, tack or suture.
34. The delivery device of claim 33, wherein the associated
fixation device comprises a crosslinking agent.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of application
Ser. No. 12/715,737, filed on Mar. 2, 2010, which is a divisional
of application Ser. No. 11/712,684, filed Feb. 28, 2007. This
application is also a continuation-in-part of application Ser. No.
11/975,072, filed Oct. 17, 2007, which is a continuation-in-part of
application Ser. No. 11/726,790, filed Mar. 22, 2007. This
application claims the benefit of Provisional Patent Application
No. 61/348,977, filed on May 27, 2010. All of the foregoing
applications are incorporated by reference herein
BACKGROUND
[0002] 1. Field of the Invention
[0003] The present invention relates to protein crosslinking
reagents for the surgical repair of torn knee menisci in humans or
similar connective tissue structures in animals such as the stifle
joint meniscus in equines.
[0004] 2. Related Art
[0005] The menisci of the knee are a pair of crescent-shaped
fibrocartilaginous structures attached to the planar apical surface
of the tibia. They contact the outer region of the femoral
articular cartilage surface and as such play an important role in
both load transmission and in maintaining the stability of the
joint [1-6].
[0006] While 65-75% of the mass of the menisci consists of water,
the remaining constituents are primarily proteins with the most
common (75%) being type I collagen [7], and damage to this tissue
is one of the most common causes of knee injury and results in
surgery to some 850,000 patients per year in the US [8]. Symptoms
of meniscal tears are primarily localized pain and swelling but, in
cases where fragments of the damaged meniscus lodge between the
articulating surfaces of the joint, catching sensations and (in the
worst case) locking of the joint can occur.
[0007] The first line of treatment for meniscal tears are
non-surgical, e.g. rest, icing, physical therapy and/or
non-steroidal anti-inflammatory drug (NSAID) treatment. Surgery is
indicated for patients who do not respond to physical therapy, who
cannot or are unable to sacrifice the time required for potentially
unsuccessful therapy and for those with locked joints.
[0008] Surgery is most commonly, but not exclusively, conducted
arthroscopically to minimize further damage to the joint and to
decrease patient recovery times. Damage to the outer periphery of
either meniscus heals more readily than that to the inner portions
[9,10], due to the lack of vasculature in the inner portion of the
meniscus [11]. For this reason, tears of the inner meniscus are
usually excised in a procedure known as a partial meniscectomy. In
the remaining cases, tears are repaired using either suture or a
variety of commercially available, fixing devices such as arrows,
darts and tacks [12-14] in order to facilitate healing of the tear.
These devices are generally constructed using biodegradable
polymers such as polylactic or polyglycolic acid so that no
subsequent surgery is required for their removal.
[0009] Although the latter class of devices provides temporary
support to the tissue as it heals, they are in general not as
strong as sutures [12,13]. However, because their use results in
substantially reduced operating times and risk of complications to
the patient, they are increasingly gaining favor [12,13].
[0010] While the above represents the most common approaches to the
treatment of meniscal tears, other therapeutic modalities for
meniscal repair can be used or are being explored experimentally.
These include: stem cell therapy [15,16]; trephination from the
vascular to avascular region to facility greater nutrient flow and
promote in-growth of vasculature [17-19]; micro-fracture of the
intercondylar notch which may release cytokines or autologous stem
cells to aid in the repair process [20]; thermal welding of the
tear [21]; enhancement of fibroblast proliferation using RF
radiation [22,23]; use of fibrin clots to both provide stimuli for
both chemotaxis and proliferation of regenerative cells [24-26],
sometimes in conjunction with laser soldering [27]; meniscal or
synovial rasping to promote healing via the release of growth
factors from the tissue [28-31]; and synovial flap grafting at the
repair site to provide vasculature [32].
[0011] In addition meniscal replacement using both artificial
implants and allografts is becoming a treatment option in the case
of severe tears where meniscectomy is the only other treatment
option [33-40]. In this respect, the possibility of stabilizing
allografts and artificial implants against biodegradation using ex
vivo protein crosslinking has been explored [41-44]. The inventors
are, however, unaware of any prior art with regard to crosslinking
of the native meniscus in situ.
SUMMARY
[0012] In one aspect, a method of treating a tear in a knee
meniscus of a patient in need of such treatment is provided. The
method includes exposing the torn knee meniscus to a protein
crosslinker (an agent that crosslinks protein) during surgery to
repair the tear. In particular embodiments, exposing includes: a)
injecting the crosslinker into a knee joint capsule containing the
torn knee meniscus; b) injecting the crosslinker into or onto the
torn knee meniscus; or c) contacting the torn knee meniscus with a
delivery device comprising the crosslinker; or d) any combination
thereof. The crosslinker is a compound or substance that can
crosslink proteins. The delivery device in any embodiment can
include a patch or fixation device comprising the crosslinker. The
fixation device may be an arrow, dart, tack or suture.
[0013] A patch or fixation device may be biodegradable or
non-biodegradable, and may comprise a basic salt, which may be an
inorganic or organic basic salt. In embodiments with a patch, the
patch may be porous, and may have crosslinker embedded in the pores
of the patch. A crosslinker in a patch may be adhered to one side
of the patch as part of a semi-solid formulation.
[0014] The patch or fixation device may in addition be coated with
one or more layers of crosslinker-containing biodegradable polymer.
When more than one layer is present, each layer may contain a basic
salt, and may contain the same or different basic salt as another
layer. In addition, each layer may contain the same or different
crosslinker as another layer. In some embodiments, the crosslinker
varies from layer to layer.
[0015] The patch may be affixed to the meniscus with a
bio-compatible adhesive. In addition, the patch may be affixed to
the meniscus by an associated fixation device such as an arrow,
dart, tack or suture. The associated fixation device may itself
include a crosslinker, which may be the same or different
crosslinker as that in the patch.
[0016] In some embodiments, the torn knee meniscus is treated
without contracting collagen fibers in the torn knee meniscus by
heating.
[0017] In another aspect, a delivery device for contacting the knee
meniscus is provided. The delivery device comprises a protein
crosslinker.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] For a more complete understanding of the present invention,
reference is now made to the following descriptions taken in
conjunction with the accompanying drawings, in which:
[0019] FIG. 1 is a drawing depicting a stylized human knee meniscus
with a "parrot beak" type tear.
DETAILED DESCRIPTION
[0020] One aspect relates to various biodegradable fixation devices
that contain one or more protein crosslinking reagents for the
surgical repair of tears of the meniscus of the knee in humans or
similar connective tissue structures in animals such as the stifle
joint meniscus in equines. Also described are associated methods
for repair of tears of the knee meniscus in humans or similar
connective tissue structures in animals such as the stifle joint
meniscus in equines.
[0021] The devices can take various forms including, but not
limited to, sutures, tacks, arrows and darts. These devices can be
produced using any biodegradable and biocompatible polymer or
mixtures of polymers such as, but not limited to, polylactic acid
or poly glycolic acid. One or more crosslinking agents may be
incorporated into the device. Additionally, the crosslinker can be
incorporated into a biodegradable patch which is overlain onto the
damaged area of the meniscus during surgery. Alternatively this
patch could be made of a non-degradable material and removed at a
time following surgery once sufficient crosslinker has been
released to facilitate tissue repair.
[0022] Following surgery, these reagents are slowly released from
the device as it degrades and thereby enter into, and react with,
the tissue to form covalent crosslink bonds. These bonds serve to
both strengthen the tissue against further and/or future tearing
and also increase the permeability of the tissue to nutrients from
the blood supply, thereby enhancing the natural healing process. In
addition, the increase in tissue permeability conferred by the
crosslinking will increase the proportion of meniscal tear patients
who can be treated surgically since healing using current methods
can only occur in regions with sufficient vascular nutrient
supply.
[0023] Another aspect relates to the treatment of meniscal tears
during surgery with protein crosslinking reagents to modify the
mechanical properties and permeability of the meniscal tissue in
order to reduce the possibility of further tearing, increase the
strength of the tissue and enhance the natural repair process.
[0024] Crosslinking of tissue is used extensively to modulate both
the mechanical properties and chemical stability of collagenous
tissues [45-52]. Historically, crosslinking has been conducted ex
vivo to modulate the mechanics and stability of tissue implants,
and has been considered with respect to producing allografts for
meniscal implant [41], but was not directed at treatment of native
meniscal tissues in vivo and in situ, in the tissues original and
natural position. Approaches aimed at injection of crosslinkers
into native, unmodified tissues in vivo and in situ are also being
developed by the inventors (U.S. Pat. No. 7,435,722, and U.S.
patent application Ser. No. 10/230,671, both incorporated by
reference herein) and others [53] for treatment of the spinal
disc.
[0025] Use of crosslinking agents and their subsequent reaction
with the tissue of the torn meniscus would provide two possible
benefits when used in conjunction with current technologies.
Firstly, the crosslinker will confer increased tear resistance to
the tissue and reduce the possibility of further propagation of the
tear as it heals (U.S. application Ser. No. 11,712,684,
incorporated by reference herein). This would in turn ameliorate
the main disadvantage of fixation devices compared to sutures while
maintaining their benefits. If the crosslinker delivery-fixation
device is a suture or another device capable of tissue fixation,
the crosslinker delivery will further augment the tear resistance
of the repair. Secondly, crosslinking has been shown to increase
the permeability of collagenous tissues [41,54,55] and thus may
increase the permeability of the meniscus. It has been shown that
the avascular portions of the meniscus (which do not heal well, if
at all, in vivo) are capable of healing in vitro when supplied with
sufficient nutrients [11]. Thus the resulting increased supply of
nutrients and oxygen to the avascular tissue may both increase the
success of the procedure for deeper tears as well as increase the
depth at which a tear is considered as a candidate for repair
versus meniscectomy.
[0026] Particular embodiments combine the beneficial properties of
protein crosslinking to improve upon currently used surgical
techniques for meniscal repair.
[0027] In some embodiments, a torn knee meniscus is treated without
contracting collagen fibers in the torn knee meniscus by heating.
Heat denaturation of collagenous tissues degrades the tissue by
disruption of native crosslinks and tissue structure. The device
and methods of exposing the meniscus tissues to the crosslinker may
be applied to non-heated, unmodified, native tissues. Thus, the
device and methods may be applied without heating, contracting or
denaturing the native tissue, or any combination thereof. The
native tissue crosslinks are thus augmented or increased by number
by exposure to the crosslinker. In some embodiments, the in situ
crosslinking method and/or devices may be applied to previously
implanted non-native tissue implants or meniscus replacement
materials that have not been denatured and/or shrunken by
heating.
[0028] In some embodiments, the meniscal tissue is pre-treated
prior to, or instead of repair by direct injection of crosslinking
solution into the capsule of the knee joint or onto or into the
damaged tissue itself prior to repair of the tissue. This treatment
strengthens the tissue, increases tear resistance, and, in
addition, allows for the surgical repair of some tears that will
not normally be candidates for repair surgery (due to their
inability to heal because of their distance from the blood supply)
by increasing the permeability of the tissue. Following injection,
the crosslinker diffuses into, and crosslinks, the meniscal tissue,
strengthening and increasing tear resistance of the tissue, while
also improving the ability of nutrients from the outer vascular
regions to diffuse into the inner regions to promote natural
healing over a larger area of the meniscus.
[0029] In some embodiments, the crosslinker is incorporated into
the fixation device itself. Thus, the crosslinker is then released
into the tissue in a sustained manner following surgery as the
fixation device degrades providing the benefits in physical
properties and permeability described above.
[0030] Solid or liquid crosslinker may be incorporated into the
device by addition to the molten polymer prior to casting, molding
or spinning Alternatively the crosslinker may be co-solubilized
with the polymer in a suitable solvent (for example, acetone) and
then incorporated into the device by removal of the solvent by
evaporation or by precipitation (for example, by the addition of
ethanol) of the polymer as described previously [56,57]. The
crosslinker and polymer may also be solubilized separately and
mixed prior to precipitation in either the same solvent or
different (miscible) solvents. Also, the solid crosslinker may also
be mixed into the polymer gum formed by precipitation of
solubilised polymer and prior to molding. The rate of crosslinker
release can be controlled by varying the amount or concentration of
the crosslinker incorporated into the device as well as by
selecting polymers or other materials with differing in vivo
degradation rates.
[0031] Alternatively the crosslinker may be co-solubilized with the
polymer in a suitable solvent, solubilized separately in the same
solvent and then mixed, or solubilized separately in different
miscible solvents and then mixed, and a pre-formed fixation device
immersed in this solution. Following removal of the fixation device
and evaporation of the solvent, a fixation device containing an
outer layer of biodegradable plastic-embedded crosslinker will be
produced. The polymer in the outer layer may be different to that
of the underlying device both in chain length and/or composition
and may be varied, for example, in order to provide different
release rates of crosslinker as needed. Additionally, the rate,
duration and extent of crosslinker release can be controlled by
varying the amount or concentration of the crosslinker incorporated
into solvent solution (and therefore the outer layer of the device)
as well as by sequential dipping/drying of the fixation device into
the crosslinker/polymer/solvent mixture to produce different
thicknesses of crosslinker-containing polymer at the surface of the
device. Additionally, several crosslinker impregnated outer layers
may be used with varying crosslinker amount or concentration and
polymer compositions such that the rate of release of crosslinker
can be varied as desired. For instance, an initial high rate of
crosslinker release can be followed by a low rate of crosslinker
release for an extended length of time.
[0032] It has been previously shown that many crosslinking reagents
act less efficiently at low pH [58]. In addition, some
biodegradable polymers degrade to form acidic compounds (for
example polylactic acid and polyglycolic acid). In fact, tissue
acidification during polymer breakdown has been a concern
previously and incorporation of basic inorganic salts into the
polymer matrix has been shown to be effective in maintaining an
elevated pH [59].
[0033] In some embodiments in cases where low-pH sensitive
crosslinkers (for example, genipin, methylglyoxal) are used in
conjunction with polymers that degrade to form acidic compounds
(for example, polylactic or polyglycolic acids), basic salts are
also incorporated as solid suspensions into the polymer matrix.
Such salts could be inorganic (for example, but not limited to,
calcium carbonate, calcium hydroxyapatite or sodium bicarbonate) or
organic (for example, but not limited to,
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).
[0034] In some embodiments, the crosslinker is impregnated by one
of the methods described above into a flat, biodegradable polymer
patch. The patch could contain pH conditioning agents and multiple
layers of crosslinking agents as described above. The patch (which
could be rolled up and inserted via a catheter) is laid over the
repaired tissue such that crosslinker is delivered to the meniscus
as the patch dissolves and while the patch offers some physical
protection to the damaged meniscal tissue as it heals. The surface
of the patch opposite to the meniscus additionally provides a
smooth bearing surface to the articular cartilage of the femur. In
addition the patch may be attached to the tissue using fixation
devices such as, but not limited to, arrows, darts, tacks or
suture. These fixation devices may or may not contain additional
(including different) crosslinking agent. The patch may also be
attached using a suitable biocompatible adhesive. Non-limiting
examples of suitable adhesives would be poly(glycerol-co-sebacate
acrylate) [60], oleic methyl esters [61] or alkyl ester
cyanoacrylates [62].
[0035] In some embodiments, the material of the patch consists of a
non-absorbable polymer. The patch is placed onto the meniscus
during the arthroscopic procedure and can be removed at a
subsequent time. Alternatively, the patch may be designed to remain
inside the knee as a permanent implant to supplement the mechanical
function of the meniscus. The patch may be attached to the meniscus
as stated above. Possible, non-limiting, polymers include
polyvinylacetate, polyvinylchloride, polypropylene,
polyetheretherketone (PEEK), polysulfone, polyethersulfone,
polytetrafluoroethylene, polyethylene, polyurethane, polyetherimide
and polycarbonate. The non-absorbable patch is either coated or
impregnated with crosslinker. The material of the patch could be
porous so that the crosslinker or combination of crosslinkers is
imbedded within the pores, or non-porous and coated with
crosslinker. In the case of a porous patch, the size and the
tortuosity of the pores can be varied in order to control the
release rate and duration of release of the imbedded
crosslinker(s). The crosslinker could be in solid form, in solution
in a suitable carrier or dissolved or suspended in a semi-solid
formulation. Alternatively the crosslinker is encapsulated within
micro- or nano-particles which are suspended in any of the above
matrices or attached directly, either covalently or non-covalently
to the surface of the non-absorbable patch. Also, the crosslinker
could be incorporated into a biodegradable (absorbable) polymer and
then used to either coat or impregnate the non-absorbable
patch.
[0036] A large number of protein crosslinkers could be used in
conjunction with the present invention. Some such crosslinkers that
have been used in the area of tissue engineering include, but are
not limited to: D- or L-Threose [63], genipin [64-67],
Methylglyoxal [68], 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride [69], proanthrocyanidin [47] and glutaraldehyde
[70-72]. In particular embodiments, the crosslinker may be a single
crosslinker or a combination of two or more crosslinkers. It has
been shown that the conditions that confer optimal reactivity of
such crosslinkers differ between reagents [58] and that in some
cases other chemicals can enhance their reactivity [53]. In
addition, some detergents can also enhance the penetration of
crosslinkers through collagenous tissues and therefore help to
enhance their ability to crosslink the tissue[53]. Thus, some
embodiments may include a chemical or detergent, or any combination
thereof, that enhances the crosslinking ability of the
crosslinker.
[0037] As one embodiment, the application method involves a direct
injection of crosslinker in a buffered reagent into the torn
meniscus. The crosslinker can be selected from several known
minimally toxic crosslinking agents such as genipin at a level of
up to 1200 micromoles and concentration of at least 5 mM
(preferably 20-100 mM) and the buffer can be 25-250 mM EPPS
4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS)
(preferably approximately 50 mM) at a pH of 7-10 (preferably 8) and
optionally contain 25-250 mM of a phosphate salt (preferably 50 mM)
to facilitate the crosslinking reaction and also optionally contain
a co-solvent such as dimethyl sulfoxide (at 1-50%, preferably
10-20%) to increase the solubility of the crosslinker.
[0038] In some embodiments, the crosslinker and conditioning agents
are imbedded into a biodegradable meniscus fixation dart. The
crosslinker can be any of several known minimally toxic
crosslinking agents such as genipin or methylglyoxal at a level of
about 1-10 mg per dart, though more can also be incorporated.
Additionally the fixation device can also optionally contain an
alkaline salt such as calcium hydroxyapatite to maintain an
elevated pH as the device degrades at a level of about 5-50% by
weight of the polymer (preferably about 15-30%).
[0039] In some embodiments, the crosslinker and conditioning agents
are imbedded into a biodegradable suture suitable for meniscus
repair using standard repair techniques. The crosslinker can be any
of several known minimally toxic crosslinking agents such as
genipin or methylglyoxal at a level of about 0.1-10% by weight of
the polymer (preferably about 1-5%). Additionally the suture can
also optionally contain an alkaline salt such as sodium bicarbonate
to maintain an elevated pH as the device degrades at a level of
about 5-50% by weight of the polymer (preferably about 5-15%).
[0040] In some embodiments, the crosslinker and conditioning agents
are imbedded into a biodegradable meniscus repair patch. The
crosslinker can be selected from any of several known minimally
toxic crosslinking agents such as genipin at a level of about 1-250
mg per patch (preferably about 5-20 mg). Additionally the patch can
also optionally contain an alkaline salt such as calcium carbonate
to maintain an elevated pH as the device degrades at a level of
about 5-50% by weight of the polymer (preferably about 15-30%). The
crosslinker embedded into the patch may, therefore, be incorporated
into a formulation that is designed to optimize its activity by the
suitable adjustment or addition of, but not exclusively, pH, ionic
strength, cations, anions, phosphate ions, and/or surfactants.
[0041] In addition, different crosslinkers can exert different
mechanical effects [53]. Thus combination of crosslinkers may also
be incorporated into embodiments in order to modulate the final
mechanical properties of the meniscal tissue. Thus the fixation
device may contain a mixture of two or more crosslinking
agents.
[0042] In some embodiments the bulk of the fixation device or patch
contains one or more crosslinkers that are incorporated into the
device during the molding stage as described above. The device is
then coated using a solvent mixture as described above but
containing a different crosslinker or mixture of crosslinkers.
Alternatively the device may be coated with additional layers of
material by applying molten polymer containing crosslinker with or
without additional agents, or a solvent-precipitated polymer gum
containing crosslinker with or without additional agents.
[0043] Thus the release of different crosslinkers is controlled
temporally by the order in which they are encapsulated. For
example, a device might contain a crosslinker that increases tissue
tear resistance but be coated with a crosslinker that
preferentially increases permeability. In this manner the device
will first enhance permeability of the tissue to both rapidly aid
in the initiation of natural repair and prepare the tissue for
ready diffusion of the second crosslinker, and only later release a
crosslinker to strengthen the tissue. Alternatively, the outer
layer may contain a strengthening crosslinker to provide immediate
improvements in meniscal tear resistance while the crosslinker that
enhances permeability is released later to help facilitate natural
repair.
[0044] Referring to FIG. 1, a stylized human knee meniscus 2 with a
"parrot beak" type tear 4 is depicted. Following surgical repair, a
patch 6 of crosslinker-impregnated material is placed over the
damaged tissue. The shaded area 8 depicts the position of the patch
following attachment. The patch may additionally be attached using
typical surgical fixation devices or by addition of a suitable
biocompatible solvent or adhesive to the side of the patch in
contact with the meniscus. Over time crosslinker will diffuse out
of the patch and into the tissue, both strengthening it and
facilitating the diffusion of nutrients into the damaged area by
increasing the tissue permeability.
[0045] In applying the methods and devices of the current
application, a patient may be a person or an animal. Further,
embodiments that involve the knee meniscus may be applied to
similar connective tissue structures in animals, such as the stifle
joint meniscus in equines. Thus, where embodiments are described in
terms of the knee meniscus, other embodiments substituting the knee
meniscus with similar connective tissue structures in animals are
contemplated.
[0046] The present invention may be better understood by referring
to the accompanying examples, which are intended for illustration
purposes only and should not in any sense be construed as limiting
the scope of the invention.
EXAMPLE 1
[0047] A radial tear of a human knee meniscus may be repaired by
the present methods and devices in a number of embodiments. Some
embodiments involve implementation of standard arthroscopic
procedures for meniscal repair using darts containing a
crosslinking and a pH modulating reagent. The fixation darts are
manufactured as follows. One gram of 50:50
poly-D,L-lactide-co-glycolide polymer (average molecular weight of
53 kDa) is dissolved in 6 ml of acetone and then precipitated by
addition of 10 ml of pure ethanol. Two hundred mg of sodium
bicarbonate and 6 mg of genipin crosslinker are added to and mixed
with the precipitated polymer prior to using the mixture to mould
three meniscal dart devices which are dried under vacuum to
solidify the polymer and remove the solvents.
EXAMPLE 2
[0048] Some embodiments involve implementation of standard
arthroscopic procedures for meniscal repair using biodegradable
sutures which are produced by extruding polydioxanone in the
presence of 10% (w/w) of a 40% solution of methylglyoxal.
EXAMPLE 3
[0049] Some embodiments involve direct injection into the meniscal
tissue in the region of the tear a buffered crosslinking reagent.
The injection may be administered using standard sterile
intracapsular injection techniques and fluoroscopic, arthroscopic,
or any equivalent or superior imaging technology and techniques
that allow for simultaneous injections. The injected solution
contains 40 mM genipin in a buffer consisting of 50 mM
3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS) and
50 mM sodium triphosphate at a pH of 8.0. The patient should avoid
flexion-extension or weight bearing of the knee for a period of
time following the injection, approximately 1 hour, to allow for
diffusion of the reagent and initial crosslink formation within the
meniscal tissue, followed by a period of light movement and
intermittent weight bearing to encourage further movement through
the tissue of unreacted reagent and to aid in the introduction of
oxygen to expedite the crosslinking reactions. A direct injection
of this type can be followed immediately or at a later date with
use of a crosslinker impregnated repair device such as a dart or
suture. Alternatively, the direct injection of a buffered
crosslinking reagent into the meniscus can follow meniscal repair
using standard fixation devices or crosslinker impregnated fixation
devices.
EXAMPLE 4
[0050] Some embodiments involve arthroscopic or minimally invasive
delivery and fixation of a meniscal repair patch to the inferior or
superior articular surface of the torn meniscus. The meniscal
repair patch is prepared from 2 grams of poly lactic acid by
dissolving the polymer in 12 ml of acetone and then precipitating
by addition of 20 ml of pure ethanol. Six hundred mg of calcium
carbonate and 20 mg of genipin crosslinker are added to and mixed
with the precipitated polymer prior to molding into the final
device and drying under vacuum. The patch may or may not be
attached to the meniscal tissue using fixing devices such as darts,
tacks or sutures which may or may not also contain crosslinking
agents (for example, as in Example 1).
EXAMPLE 5
[0051] The improvement in meniscal mechanical properties including
tear resistance due to the present methods and devices can be
measured using human or bovine cadaveric meniscal explants and in
vitro experimental methods briefly summarized here. An appropriate
number of tissue specimens are included in the study according to
previously documented variances in mechanical properties of the
selected tissue type. According to the inventors' previously
published protocol (Slusarewicz, et al., 2011, Spine, "Optimization
of protein crosslinking formulations . . . " [49]), two adjacent
circumferential dumbbell-shaped specimens are excised from the
inner region of sixteen medial or lateral menisci for tensile
testing. One specimen from each pair is treated with a crosslinking
agent either via soaking in a buffered crosslinking solution such
as 40 mM genipin in a buffer consisting of 50 mM
3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS) and
50 mM sodium triphosphate at a pH of 8.0, or injecting
approximately 0.1-0.5 ml of such a buffered crosslinking reagent
using a small, greater than 20 gauge, or insulin-sized needle.
Control specimens are mock-treated (soaked or injected) using the
same buffer without crosslinker. Samples are subjected to
strain-rate controlled tensile testing until failure using a
suitable materials testing system and soft-tissue compatible clamps
to hold the ends of the dumbbell-shaped specimens without tearing
or damaging the specimens at the clamping site. The data is
normalized using the specimen's cross-sectional area measured with
a rotating laser micrometer, and the yield stress, modulus,
resilience, ultimate tensile stress, and toughness are calculated.
Comparisons between groups are evaluated using Wilcoxon
non-parametric paired analysis. The effect of the crosslinking
treatment is evidenced by a statistically significant and greater
than 20% improvement in at least one of the measured mechanical
properties following crosslinking treatment.
[0052] Fatigue degradation studies are conducted similarly, with
the tensile tests conducted on repetitively cycled (1000 or greater
numbers of pseudophysiologic cycles) or non-cycled pairs of
specimens. Previous experience conducting these tests suggest that
a minimum of 8-pairs of crosslinked and buffer treated specimens
are required to show a statistically significant and meaningful
difference in fatigue resistance. The effect of the crosslinking
treatment is evidenced by a statistically significant and 30% or
greater reduction in some elastic-plastic or viscoelastic property
degradation due to repetitive cycling. For example, crosslinker
treated meniscus specimens demonstrate a greater than 30% reduction
in the increase in stress relaxation due to repetitive loading
compared to the sham treated meniscus specimens.
[0053] Transverse (transverse to the long axis of the meniscus
specimens) tear resistance testing is conducted in the following
manner. 2 mm (axial).times.8 mm (transverse) inner meniscus
longitudinal (circumferential) specimens are dissected from the
rear half of sixteen lateral or medial knee menisci. A transverse
directed v-shaped notch defect is created with a scalpel in the
mid-section of the specimen. The thickness of the specimen in the
region of the defect and the distance between the tip of the defect
and the edge of the specimen opposite the defect are measured using
a laser non-contacting micrometer. The specimen is held taunt with
its ends fixed in soft-tissue compatible clamps, while a metal
cylinder is positioned in the notch defect and then pulled
transversely through the specimen while force (on the pin) and
displacement are recorded. A longitudinal (long axis of the
meniscus specimen) tear testing protocol involves the use of
sixteen front (cephalo) hemi-lateral meniscus specimens which are
microtomed and dissected into ASTM style "pants legs" tear samples
(12 mm.times.2 mm.times.circumferential length with a cut following
the longitudinal contour leaving 8 mm uncut) for longitudinal tear
testing. The thickness of the specimen in the uncut region and the
distance between the "crotch" of the pants cut and the edge of the
specimen opposite the cut are measured using a laser non-contacting
micrometer. These material tear-propogation tests are commonly
performed. Briefly, the ends of the specimen "legs" are pulled in
opposite directions using a suitable materials testing system and
soft-tissue compatible clamps at a constant rate of displacement
while measuring applied force and displacement. Tear testing
specimens are divided equally into crosslinker treated and sham
treated groups. For both transverse and longitudinal tear tests,
peak tear force and total energy to propagate the tear are compared
between groups using Mann-Whitney non-parametric statistical tests.
The effect of the crosslinking treatment is evidenced by a
statistically significant and greater than 20% increase in peak
force and total energy required to propagate a tear through the
meniscal tissue in both transverse and longitudinal directions.
EXAMPLE 6
[0054] Improvement in meniscal cell viability following
crosslinking treatment can be quantified experimentally in a number
of ways. One method of quantifying this improvement is to measure
the increase in tissue permeability associated with a crosslinking
treatment of the present invention. Permeability is analyzed using
a Franz cell system. Franz cells are glass chambers consisting of
lower receptor and upper donor chambers with the sample sandwiched
between them. The lower chamber is filled with a suitable buffer
while the donor chamber contains a suitable small probe molecule
dissolved in buffer. The permeability of the tissue governs the
rate of the diffusion and presence of the probe molecule in the
receptor fluid. A suitable probe molecule penetrates but doesn't
bind to the tissue. Suitable probe molecules can be chromophores
such as pnitrophenol or fluorophores such as fluorocein. In either
case, a simple colorimetric or fluorometric (if greater sensitivity
is required) assay is used to quantify the appearance of the probe
in the receptor chamber. The baseline kinetics of penetration for
normal meniscus is first quantified. Six (based on prior work of
Hunter, et al., 2005, Journal of Orthopaedic Research [26]) tissue
samples are treated with crosslinking reagent either by soaking in
40 mM genipin in a buffer consisting of 50 mM
3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS) and
50 mM sodium triphosphate at a pH of 8.0, or by a direct injection
of the buffered crosslinking reagent into the meniscus specimen as
described in Example 5 above. An additional six controls are
treated in a similar manner with buffer alone. Samples are then cut
to the same thickness using a microtome. Kinetic analysis is
conducted by periodically sampling and analyzing the receptor
fluid, facilitating quantitative determination of tissue
permeability. The effect of the crosslinking treatment suggesting
improved cell viability in this largely avascular tissue is
evidenced by a statistically significant and greater than 40%
increase in tissue permeability.
REFERENCES
[0055] The following publications are incorporated by reference
herein: [0056] 1. Allen P R, Denham R A, Swan A V. Late
degenerative changes after meniscectomy. Factors affecting the knee
after operation. J. Bone Joint Surg. Br. 1984; 66:666-71. [0057] 2.
Fairbank T J. Knee joint changes after meniscectomy. J. Bone Joint
Surg. Am. 1948; 30B:664-70. [0058] 3. Jorgensen U, Sonne-Holm S,
Lauridsen F et al. Long-term follow-up of meniscectomy in athletes.
A prospective longitudinal study. J. Bone Joint Surg. Br. 1987;
69:80-3. [0059] 4. Walker P S, Erkman M J. The role of the menisci
in force transmission across the knee. Clin. Orthop. Relat Res.
1975; 184-92. [0060] 5. Fu F H, Thompson W O. Motion of the knee
meniscus during knee flexion. In: Mow V C, Arnoczky S P, Jackson D
W, eds. Knee Meniscus: Basic and Clinical Foundations. New York,
N.Y.: Raven Press, 1992:75-89. [0061] 6. Levy I M, Torzilli P A,
Fisch I D. The contribution of the menisci to the stability of the
knee. In: Mow V C, Arnoczky S P, Jackson D W, eds. Knee Meniscus:
Basic and Clinical Foundations. New York, N.Y.: Raven Press,
1992:107-15. [0062] 7. Proctor C S, Schmidt M B, Whipple R R et al.
Material properties of the normal medial bovine meniscus. J.
Orthop. Res. 1989; 7:771-82. [0063] 8. Arendt E A. Orthopaedic
Knowledge Update: Sports Medicine 2. Rosemont, Ill.: American
Academy of Orthopaedic Surgeons, 1999. [0064] 9. Jakob R P, Staubli
H U, Zuber K et al. The arthroscopic meniscal repair. Techniques
and clinical experience. Am. J. Sports Med. 1988; 16:137-42. [0065]
10. Rosenberg T D, Scott S M, Coward D B et al. Arthroscopic
meniscal repair evaluated with repeat arthroscopy. Arthroscopy
1986; 2:14-20. [0066] 11. Hennerbichler A, Moutos F T,
Hennerbichler D et al. Repair response of the inner and outer
regions of the porcine meniscus in vitro. Am. J. Sports Med. 2007;
35:754-62. [0067] 12. Barber F A, Herbert M A, Richards D P. Load
to failure testing of new meniscal repair devices. Arthroscopy
2004; 20:45-50. [0068] 13. Barber F A, Herbert M A. Meniscal repair
devices. Arthroscopy 2000; 16:613-8. [0069] 14. Rankin C C, Lintner
D M, Noble P C et al. A biomechanical analysis of meniscal repair
techniques. Am. J. Sports Med. 2002; 30:492-7. [0070] 15. Izuta Y,
Ochi M, Adachi N et al. Meniscal repair using bone marrow-derived
mesenchymal stem cells: experimental study using green fluorescent
protein transgenic rats. Knee. 2005; 12:217-23. [0071] 16. Yamasaki
T, Deie M, Shinomiya R et al. Meniscal regeneration using tissue
engineering with a scaffold derived from a rat meniscus and
mesenchymal stromal cells derived from rat bone marrow. J. Biomed.
Mater. Res. A 2005; 75:23-30. [0072] 17. Zhang Z, Arnold J A.
Trephination and suturing of avascular meniscal tears: a clinical
study of the trephination procedure. Arthroscopy 1996; 12:726-31.
[0073] 18. Fox J M, Rintz K G, Ferkel R D. Trephination of
incomplete meniscal tears. Arthroscopy 1993; 9:451-5. [0074] 19.
Cook J L, Fox D B. A novel bioabsorbable conduit augments healing
of avascular meniscal tears in a dog model. Am. J. Sports Med.
2007; 35:1877-87. [0075] 20. Freedman K B, Nho S J, Cole B J.
Marrow stimulating technique to augment meniscus repair.
Arthroscopy 2003; 19:794-8. [0076] 21. Imakiire N, Kotani A, Ishii
Y. Experimental study on thermal welding for the knee meniscal
white zone. J. Orthop. Sci. 2003; 8:683-92. [0077] 22. Hatayama K,
Higuchi H, Kimura M et al. Histologic changes after meniscal repair
using radiofrequency energy in rabbits. Arthroscopy 2007;
23:299-304. [0078] 23. Lopez M J, DeTemple L A, Lu Y et al. The
effects of monopolar radiofrequency energy on intact and lacerated
ovine menisci. Arthroscopy 2001; 17:613-9. [0079] 24. Arnoczky S P,
Warren R F, Spivak J M. Meniscal repair using an exogenous fibrin
clot. An experimental study in dogs. J. Bone Joint Surg. Am. 1988;
70:1209-17. [0080] 25. Sethi P M, Cooper A, Jokl P. Technical tips
in orthopaedics: meniscal repair with use of an in situ fibrin
clot. Arthroscopy 2003; 19:E44. [0081] 26. van Trommel M F,
Simonian P T, Potter H G et al. Arthroscopic meniscal repair with
fibrin clot of complete radial tears of the lateral meniscus in the
avascular zone. Arthroscopy 1998; 14:360-5. [0082] 27. Forman S K,
Oz M C, Lontz J F et al. Laser-assisted fibrin clot soldering of
human menisci. Clin. Orthop. Relat Res. 1995; 37-41. [0083] 28.
Ochi M, Uchio Y, Okuda K et al. Expression of cytokines after
meniscal rasping to promote meniscal healing. Arthroscopy 2001;
17:724-31. [0084] 29. Okuda K, Ochi M, Shu N et al. Meniscal
rasping for repair of meniscal tear in the avascular zone.
Arthroscopy 1999; 15:281-6. [0085] 30. Talley M C, Grana W A.
Treatment of partial meniscal tears identified during anterior
cruciate ligament reconstruction with limited synovial abrasion.
Arthroscopy 2000; 16:6-10. [0086] 31. Nakhostine M, Gershuni D H,
Anderson R et al. Effects of abrasion therapy on tears in the
avascular region of sheep menisci. Arthroscopy 1990; 6:280-7.
[0087] 32. Jitsuiki J, Ochi M, Ikuta Y. Meniscal repair enhanced by
an interpositional free synovial autograft: an experimental study
in rabbits. Arthroscopy 1994; 10:659-66. [0088] 33. Tienen T G,
Heijkants R G, de Groot J H et al. Replacement of the knee meniscus
by a porous polymer implant: a study in dogs. Am. J. Sports Med.
2006; 34:64-71. [0089] 34. Stone K R, Steadman J R, Rodkey W G et
al. Regeneration of meniscal cartilage with use of a collagen
scaffold. Analysis of preliminary data. J. Bone Joint Surg. Am.
1997; 79:1770-7. [0090] 35. Stone K R, Rodkey W G, McKinney L A et
al. Autogenous replacement of the meniscus cartilage: analysis of
results and mechanisms of failure. Arthroscopy 1995; 11:395-400.
[0091] 36. Stone K R, Rodkey W G, Webber R et al. Meniscal
regeneration with copolymeric collagen scaffolds. In vitro and in
vivo studies evaluated clinically, histologically, and
biochemically. Am. J. Sports Med. 1992; 20:104-11. [0092] 37. Stone
K R, Rodkey W G, Webber R J et al. Future directions.
Collagen-based prostheses for meniscal regeneration. Clin. Orthop.
Relat Res. 1990; 129-35. [0093] 38. Milachowski K A, Weismeier K,
Wirth C J. Homologous meniscus transplantation. Experimental and
clinical results. Int. Orthop. 1989; 13:1-11. [0094] 39. Garrett J
C, Steensen R N. Meniscal transplantation in the human knee: a
preliminary report. Arthroscopy 1991; 7:57-62. [0095] 40. Arnoczky
S P, Warren R F, McDevitt C A. Meniscal replacement using a
cryopreserved allograft. An experimental study in the dog. Clin.
Orthop. Relat Res. 1990; 121-8. [0096] 41. Hunter S A, Noyes F R,
Haridas B et al. Meniscal material properties are minimally
affected by matrix stabilization using glutaraldehyde and glycation
with ribose. J. Orthop. Res. 2005; 23:555-61. [0097] 42. Stone K R.
Prosthetic meniscus. ReGen Corporation. (U.S. Pat. No. 5,007,934).
3-2-0989. [0098] 43. Wisnewski P J, Powers D L, Kennedy J M.
Glutaraldehyde-cross-linked meniscal allografts: mechanical
properties. J. Invest Surg. 1988; 1:259-66. [0099] 44. Powers D L,
Davenport M E, Wisnewski P J. Glutaraldehyde-cross-linked meniscal
allografts: clinical, gross, and histological results. J. Invest
Surg. 1988; 1:249-57. [0100] 45. Charulatha V, Rajaram A. Influence
of different crosslinking treatments on the physical properties of
collagen membranes. Biomaterials 2003; 24:759-67. [0101] 46. Chuang
S Y, Odono R M, Hedman T P. Effects of exogenous crosslinking on in
vitro tensile and compressive moduli of lumbar intervertebral
discs. Clin. Biomech. 2007; 22:14-20. [0102] 47. Han B, Jaurequi J,
Tang B W et al. Proanthocyanidin: a natural crosslinking reagent
for stabilizing collagen matrices. J. Biomed. Mater. Res. A 2003;
65:118-24. [0103] 48. Slusarewicz P, Zhu K, Hedman T P. Kinetic
Characterization and Comparison of Various Protein Crosslinking
Reagents for Matrix Modification. J. Mater. Sci. Mater. Med. 2010;
DOI: 10.1007/s10856-010-3986-8. [0104] 49. Sung H W, Liang I L,
Chen C N et al. Stability of a biological tissue fixed with a
naturally occurring crosslinking agent (genipin). J. Biomed. Mater.
Res. 2001; 55:538-46. [0105] 50. Tang S Y, Sharan A D, Vashishth D.
Effects of collagen crosslinking on tissue fragility. Clin.
Biomech. (Bristol., Avon.) 2008; 23:122-3. [0106] 51. Vasudev S C,
Chandy T. Effect of alternative crosslinking techniques on the
enzymatic degradation of bovine pericardia and their calcification.
J. Biomed. Mater. Res. 1997; 35:357-69. [0107] 52. Zhai W, Chang J,
Lin K et al. Crosslinking of decellularized porcine heart valve
matrix by procyanidins. Biomaterials 2006; 27:3684-90. [0108] 53.
Slusarewicz P, Zhu K, Kirking B et al. Optimization of Protein
Crosslinking Formulations for the Treatment of Degenerative Disc
Disease. Spine 2010; In Press. [0109] 54. Boyd-White J, Williams J
C, Jr. Effect of cross-linking on matrix permeability. A model for
AGE-modified basement membranes. Diabetes 1996; 45:348-53. [0110]
55. Chuang S Y, Popovich J M, Lin L C et al. The Effects of
Exogenous Crosslinking on Hydration and Fluid Flow in the
Intervertebral Disc Subjected to Compressive Creep Loading and
Unloading. Submitted to Spine 2009. [0111] 56. Athanasiou K A,
Singhal A R, Agrawal C M et al. In vitro degradation and release
characteristics of biodegradable implants containing trypsin
inhibitor. Clin. Orthop. Relat Res. 1995; 272-81. [0112] 57.
Singhal A R, Agrawal C M, Athanasiou K A. Salient Degradation
Features of a 50:50 PLA/PGA Scaffold for Tissue Engineering. Tissue
Eng 1996; 2:197-207. [0113] 58. Slusarewicz P, Zhu K, Hedman T.
Kinetic characterization and comparison of various protein
crosslinking reagents for matrix modification. J. Mater. Sci.
Mater. Med. 2010; 21:1175-81. [0114] 59. Agrawal C M, Athanasiou K
A. Technique to control pH in vicinity of biodegrading PLA-PGA
implants. J. Biomed. Mater. Res. 1997; 38:105-14. [0115] 60.
Mandavi A, Ferreira L, Sundback C et al. A biodegradable and
biocompatible gecko-inspired tissue adhesive. Proc. Natl. Acad.
Sci. U.S.A 2008; 105:2307-12. [0116] 61. Klapperich C M, Noack C L,
Kaufman J D et al. A novel biocompatible adhesive incorporating
plant-derived monomers. J. Biomed. Mater. Res. A 2009; 91:378-84.
[0117] 62. Jonn J Y, Bobo J, Quintero J et al. Absorbable adhesive
compositions. (U.S. Pat. No. 6,620,846). 2000. US. [0118] 63.
Verzijl N, De Groot J, Ben Z C et al. Crosslinking by advanced
glycation end products increases the stiffness of the collagen
network in human articular cartilage: a possible mechanism through
which age is a risk factor for osteoarthritis. Arthritis Rheum.
2002; 46:114-23. [0119] 64. Sung H W, Chang Y, Chiu C T et al.
Crosslinking characteristics and mechanical properties of a bovine
pericardium fixed with a naturally occurring crosslinking agent. J.
Biomed. Mater. Res. 1999; 47:116-26. [0120] 65. Sung H W, Chang Y,
Chiu C T et al. Mechanical properties of a porcine aortic valve
fixed with a naturally occurring crosslinking agent. Biomaterials
1999; 20:1759-72. [0121] 66. Hedman T P, Saito H, Vo C et al.
Exogenous cross-linking increases the stability of spinal motion
segments. Spine 2006; 31:480-5. [0122] 67. Yerramalli C S, Chou A
I, Miller G J et al. The effect of nucleus pulposus crosslinking
and glycosaminoglycan degradation on disc mechanical function.
Biomech. Model. Mechanobiol. 2007; 6:13-20. [0123] 68. Wagner D R,
Reiser K M, Lotz J C. Glycation increases human annulus fibrosus
stiffness in both experimental measurements and theoretical
predictions. J. Biomech. 2006; 39:1021-9. [0124] 69. Gratzer P F,
Lee J M. Control of pH alters the type of cross-linking produced by
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) treatment of
acellular matrix vascular grafts. J. Biomed. Mater. Res. 2001;
58:172-9. [0125] 70. Wu X, Black L, Santacana-Laffitte G et al.
Preparation and assessment of glutaraldehyde-crosslinked
collagen-chitosan hydrogels for adipose tissue engineering. J.
Biomed. Mater. Res. A 2007; 81:59-65. [0126] 71. Yang S H, Hsu C K,
Wang K C et al. Tricalcium phosphate and glutaraldehyde crosslinked
gelatin incorporating bone morphogenetic protein--a viable scaffold
for bone tissue engineering. J. Biomed. Mater. Res. B Appl.
Biomater. 2005; 74:468-75. [0127] 72. Hoffmann B, Seitz D, Mencke A
et al. Glutaraldehyde and oxidised dextran as crosslinker reagents
for chitosan-based scaffolds for cartilage tissue engineering. J.
Mater. Sci. Mater. Med. 2009; 20:1495-503.
[0128] Although the present invention has been described in
connection with the preferred embodiments, it is to be understood
that modifications and variations may be utilized without departing
from the principles and scope of the invention, as those skilled in
the art will readily understand. Accordingly, such modifications
may be practiced within the scope of the invention and the
following claims.
* * * * *